anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
USP15, a pivotal member of the deubiquitinase family, plays a crucial role in orchestrating numerous vital biological processes, including the regulation of NF-κB signaling pathway and deubiquitination of proto-oncogenes. In various cancers, USP15 has been validated to exhibit up-regulated expression, impacting the initiation and progression of cancer. However, its precise mechanism in bladder cancer remains elusive. Our study shed light on the significant overexpression of USP15 in bladder cancer cells compared to normal bladder cells, correlating with a poorer prognosis for bladder cancer patients. Strikingly, attenuation of USP15 expression greatly attenuated the proliferation, migration, and invasion of bladder cancer cells. Moreover, upregulation of USP15 was found to drive cancer progression through the activation of the NF-κB signaling pathway. Notably, USP15 directly deubiquitinates BRCC3, heightening its expression level, and subsequent overexpression of BRCC3 counteracted the antitumoral efficacy of USP15 downregulation. Overall, our findings elucidated the carcinogenic effects of USP15 in bladder cancer, primarily mediated by the excessive activation of the NF-κB signaling pathway, thereby promoting tumor development. These results underscore the potential of USP15 as a promising therapeutic target for bladder cancer in the future.
1. Technical Result Increase in efficiency of treatment and widening of assortment for restoring the functions of musculoskeletal system. 2. Essence For restoring the functions of musculoskeletal system is used a medicinal means comprising leaves of burdock (Arctium), stems of nettle (Urtica urens L.), leaves of plantain (Plantago major L.) and sage (Salvia) and roots of oak (Quercus). 3. Field of Application Medicine, therapy.
PURPOSE: A composition for preventing and treating retinal disorders which includes comb slight intoxication extracts or the fractions is provided to prevent degeneration of the retina nerve cells induced from oxidative stress. CONSTITUTION: A composition for preventing and treating retinal disorders includes comb slight intoxication extracts or the fractions. The retinal disorder is the age-related macular degeneration or the glaucoma. The retinal disorder is induced by the oxidative stress. The comb slight intoxication extracts is obtained by extracting using water, alcohol of C1- C4, acetone or a mixed solvent thereof. The alcohol is either methanol or ethanol. The fractions are obtained by successively partitioning the Rheum coreanum extract by using N-hexane, methylene chloride, ethyl acetate, normal - butanol and water in order. The health supplement for preventing and treating retinal disorders includes the comb slight intoxication or the fraction thereof as an active ingredient.
Up to 18 patients will be enrolled to one of three cohorts to receive various doses of omacetaxine over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
The invention provides a cervical vertebra health care product, a health care medicines pillow of the cervical vertebra health care product and a health care collar of the cervical vertebra health care product. The cervical vertebra health care product is composed of alangium platanifolium roots, angelica sinensis, borneol, radix aconiti kusnezoffii, monkshood, radices ligustici sinensis, cassia twigs, safflower carthamus, large-leaved gentian, loranthus parasiticus, ramulus mori, lycopodium clavatum, silkworm shit, berba aristolochiae mollissimae, herba epimedii, rhizoma corydalis, caulis spatholobi, radix angelicae, ligusticum wallichii, radices sileris, roots of kudzu vine, chrysanthemum, homalomena occulta, notopterygium roots, radix clematidis, asarum and garden balsam stems. The health-care medicine pillow comprises a pillow interior, the pillow interior is filled with filling, a medicine bag is arranged above the filling, and the cervical vertebra health care product is placed in the medicine bag. The health-care collar comprises a collar body and the collar body is filled with the cervical vertebra health care product. Multiple kinds of traditional Chinese medicine for expelling wind, removing cold, promoting blood circulation, removing blood stasis, enlightening through aroma, diminishing inflammation and removing twitching are adopted and the cervical vertebra health care product can be widely applied to different kinds of cervical spondylosis. Under the circumstance that normal work is not influenced, various discomforts of headaches, feeling of fullness in the head and the like caused by acid, expansion, pain and stiffness of the neck and the shoulders can be effectively relieved or eliminated.
Participants with advanced solid tumor and moderate hepatic impairment will receive an escalating dose of sacituzumab govitecan-hziy on Days 1 and 8. The dose-escalation plan will start at 5 mg/kg and escalate to 7.5 mg/kg, and finally 10 mg/kg, if deemed to be safe. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
This invention relates to oxysteroids and oxysteroid hormones which have been identified. These oxysteroids are C27 modified sterols, particularly derivatives of intermediates in cholesterol synthesis, including lanosterol, zymosterol and desmosterol, including C27 diol and C27 acid derivatives, as well as related compounds and analogs thereof. The oxysteroids are capable of binding to or otherwise interacting with orphan nuclear receptors to result in modulation of gene expression. The invention further relates to methods of modulating the rate of cholesterol synthesis in a mammal. More specifically, the invention relates to treatment of cholesterol-related conditions which are improved or ameliorated by modulating the rate of cholesterol synthesis or cholesterol metabolism in a human in need thereof by administration of these oxysteroids, analogs or antagonists thereof. Assays for identification of analogs, antagonists or modulators of these oxysteroids are also provided.
PURPOSE:To obtain a novel substance C-1 having a carcinostatic activity, by cultivating a specific actinomyces belonging to the genus Streptomyces. CONSTITUTION:Streptomyces griseoincarnatus AJ9424 is cultivated in a culture medium containing a carbon source, nitrogen source, inorganic ions, etc. by conventional method to produce the aimed novel substance C-1. The cultivation is carried out under aerobic conditions at 4-9pH and 25-38 deg.C cultivation temperature. The resultant substance has the following properties. Shape; light red powder. Molecular weight; 410 [measured by the field desorption mass spectrometry (FD-MS) method]. Solubility; slightly soluble in water and soluble in methanol, ethanol, butanol and ethyl acetate.
PURPOSE:To achieve a higher sensitivity and accuracy of analysis, by setting the amount of an antibody at 0.01-500mug per mumol. of phospholipid or glycolipid of liposome in a reagent for immuno-analysis having an antibody immobilized while a label substance is sealed inside. CONSTITUTION:First, phospholipid or phosphosugar is made to react with a crosslinking agent in a solvent, cholesterol is added and the mixture is dried. Then, an aqueous solution containing a label solution is added and shaken to prepare a suspension of liposome, which is then made to react with a proper amount of an antibody in a buffer to immobilize the antibody on the liposome. The immobilization of the antibody is determined by measuring the density thereof before and after the reaction of the antibody with the liposome by pigment bonding method. When the antibody immobilized on the liposome is less than 0.01mug per mumol. of lipid composing the liposome, the sensitivity is poor and preservation stability is lower and non-specific reaction during the measurement is easy to occur when it is more than 500mug.
PURPOSE:To provide the titled metabolism regulating agent effective to normalize the abnormality in the magnesium concentration, and useful for the remedy and prevention of various disease such as renal disease, nervous diseases, osteometabolism abnormality, etc. by using 24, 25-dihydroxycholecalciferol as an active component. CONSTITUTION:24,25- Dihydroxycholecalciferol, especially 24R, 25- dihydroxycholecalciferol is used as an active component. The agent is preferably administered orally in various forms. The compound is mixed with a solvent such as triglyceride, corn oil, etc., and other additives such as lactose, starch, talc, magnesium stearate, sorbic acid, alcohol, physiological saline water, etc. The content of the active component in the preparation is 0.00002-4wt%, preferably 0.0002-1wt%.
Participants that are randomized to be in the usual care control group will continue on as participants in the Caring Forward Trials within Cohort Study (i.e. filling out questionnaires every 6-months). Participants will continue to participate in the Caring Forward Study until completion in March 2022.
Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
AIMS: This study aims to investigate trends in four types of adolescent mental health problems; that is, psychosomatic symptoms, depressive symptoms, suicidal ideations, and suicide attempts 2004-2020. A second aim is to investigate the moderating roles of socioeconomic status and sex in these trends.
METHODS: The analysis is based on repeated cross-sectional data 2004-2020 among grade 9 students in secondary schools in a Swedish county. In total, data from 19,873 students were included in the analysis. We fitted linear and logistic regression equations and used survey-years' coefficients to estimate the trends. We also estimated the moderating effects of socioeconomic status and sex using interactions between survey year and socioeconomic status and sex, respectively.
RESULTS: The trends in all mental health problems declined over time. Through its interaction with survey year, socioeconomic status moderated the trends; psychosomatic symptoms (B = -0.115, P<0.001), depressive symptoms (B = -0.084, P<0.001) and suicidal ideations (odds ratio 0.953, confidence interval 0.924-0.983) significantly declined over time among those with high socioeconomic status. However, socioeconomic status did not have an association with the trend in suicide attempts. Interaction between sex and year of survey was associated with significant decreasing trends in depressive symptoms and suicidal ideations only among girls.
CONCLUSIONS: Adolescent mental health problems have decreased over time, but only for adolescents with high socioeconomic status, or only in depressive symptoms and suicidal ideations for girls. The results shed light on the growing inequalities in health outcomes across levels of socioeconomic status.
Those randomized to non-trauma-focused therapy will receive present centered therapy (PCT). Originally designed as a strong comparator for psychotherapy research that included the components of "good therapy," PCT is now a bona-fide PTSD treatment suggested at the second tier in multiple clinical practice guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted.
In certain embodiments, a method for analyzing a retinal image of an eye for retinal disease includes conforming a contact portion of a patient interface to the surface of the eye. A camera stem is received by a sleeve of the patient interface. Light from the camera stem is directed by the sleeve towards the interior of the eye, and light reflected from the interior of the eye is directed by the sleeve towards the camera. Image data generated by the camera is output to a computer. Options representing actions that facilitate analysis of the retinal image are displayed at the computer. The retinal image is displayed at the computer according to the image data. A selection of an option is received by the computer. The action represented by the option is performed by the computer to facilitate analysis of the retinal image.
BACKGROUND: In hematologic cancers, including leukemia, cells depend on amino acids for rapid growth. Anti-metabolites that prevent their synthesis or promote their degradation are considered potential cancer treatment agents. Amino acid deprivation triggers proliferation inhibition, autophagy, and programmed cell death. L-lysine, an essential amino acid, is required for tumor growth and has been investigated for its potential as a target for cancer treatment. L-lysine α-oxidase, a flavoenzyme that degrades L-lysine, has been studied for its ability to induce apoptosis and prevent cancer cell proliferation. In this study, we describe the use of L-lysine α-oxidase (LO) from the filamentous fungus Trichoderma harzianum for cancer treatment.
RESULTS: The study identified and characterized a novel LO from T. harzianum and demonstrated that the recombinant protein (rLO) has potent and selective cytotoxic effects on leukemic cells by triggering the apoptotic cascade through mitochondrial dysfunction.
CONCLUSIONS: The results support future translational studies using the recombinant LO as a potential drug for the treatment of leukemia.
The invention comprises compounds of the general formula: <FORM:0856505/IV(b)/1> wherein R1 and R2, which may be the same or different, are hydrogen atoms, C1-4 alkyl radicals or acyl radicals, or, together with the adjacent nitrogen atom, they may form a heterocyclic ring which may contain an oxygen or sulphur atom, and R3 is a chlorine or bromine atom or a mercapto or alkyl mercapto radical; and the preparation thereof by the following processes: (a) where NR1R2 is an amino or heterocyclic group and R3 is a halogen atom, by reacting a 6, 7-dihalo-5, 8-quinolinequinone with HNR1R2; (b) where NR1R2 is an acyl amino group and R3 is a halogen atom, by acylating the corresponding amino compound; (c) where R3 is a mercapto group, by treating the corresponding halogeno compound with hydrogen sulphide or a salt thereof; and (d) where R3 is alkyl mercapto, by alkylating the corresponding mercapto compound or by reacting the corresponding halogeno compound with an alkali-metal mercaptile; and pharmaceutical compositions containing the products (see Group VI).  The products are active against Actinomycetes.  6, 7- Dichloro-5, 8-quinolinequinone is prepared by oxidative chlorination of 5-amino-8-hydroxy-quinoline.  6, 7- Dibromo-5, 8-quinolinequinone is prepared by treating 5-amino-8-hydroxy-quinoline with sodium bromate and hydrobromic acid.ALSO:Pharmaceutical compositions comprise compounds of the general formula:  <FORM:0856505/VI/1> wherein R1 and R2, which may be the same or different, are hydrogen atoms, C1-4 alkyl radicals or acyl radicals, or, together with the adjacent nitrogen atom, they may form a heterocyclic ring which may contain an oxygen or a sulphur atom, and R3 is a chlorine or bromine atom or a mercapto or alkyl mercapto radical, in admixture with 2-(p-aminobenzenesulphonamide) - pyrimidine or 2 - (p-aminobenzenesulphonamide) - 4 - methyl - pyrimidine combined with the 4-aminobenzenesulphothiocarbamide salt of 4-aminoethylbenzenesulphonamide and preferably an inert carrier, and if desired an analgesic such as aspirin.  The compositions may be in conventional pharmaceutical form e.g. a capsule, emulsion or solution.
Many pacemaker patients have cardiac conduction system disease and thus need ventricular pacing. Traditional ventricular pacing causes ventricular dyssynchrony that in turn causes cardiac contraction dysfunction. CRT pacing provides better ventricular synchronization, but not the optimal, especially in patients with narrow QRS. CRT non-response rate is at 30%. His bundle pacing utilizes naturel His bundle-Purkinjie system to provide optimal physiological pacing. But many pacing-indicated patients have abnormal His bundle-Purkinje system, thus His bundle pacing cannot provide optimal pacing in patients with abnormal cardiac conduction system. Moreover, the pacing threshold is high during His bundle pacing. More recently, left bundle branch pacing is proposed. However, LBBP will generate right bundle branch block pattern, another kind of weak ventricular synchronization. Thus, the investigators propose to excite the left and right bundle branches area simultaneously to normalize ventricular synchronization. The purpose of this study is to explore the electrocardiogram (ECG) characteristics of simultaneous stimulation of right and left bundle branches area.
DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
The investigator proposes to conduct a large randomized trial to test the impact of MTs (Mobility Technicians) on short and intermediate term outcomes for 3000 patients aged 65 years and older at 5 hospitals in 2 health systems. Patients will be randomized to receive supervised ambulation up to 3 times daily with a MT or to receive usual care. All participants will wear an accelerometer on their wrist to track their movement throughout the hospital stay. The study has 3 aims. First, the study will compare the mobility of patients at discharge (or 10 days) to assess the impact of the MTs on this outcome. Of particular interest is whether the use of MTs will increase the proportion of patients who can go home vs.post-acute care, and whether the improvements in mobility are sustained at 30 days. Second, the study will use predictive modeling to identify which patients are most likely to benefit from this intervention. Third, the study will assess the impact of the intervention on overall costs associated with the episode of care, including inpatient costs and the 30 days post enrollment. This information will be important to convince health systems to adopt this approach.
The proposed investigation is a randomized prospective evaluation of a Survivorship Intervention in improving the quality of care, treatment satisfaction and understanding of care in Latina and Caucasian breast cancer survivors treated in an urban academic medical center. Patients will be recruited within 6 weeks of completing their last definitive breast cancer therapy (radiation or chemotherapy). Patients will complete self administered baseline and follow-up questionnaires. Following baseline evaluation patients will be randomized to receiving either written information for follow-up care of cancer survivors published by the National Cancer Institute (Facing Forward), or the Survivorship Intervention. Patients will not be aware that they are participating in a randomized intervention. After verbally agreeing to participate they will be randomized to group A or B and will receive the corresponding consent. Patients will be re-assessed 3 and 6 months after enrollment.
BACKGROUND: Adults with frailty have palliative care needs [1] but have disproportionately less access to palliative care services [2]. Frailty affects ~4000 patients admitted to hospital per day in the UK [3], making the hospital admission a unique opportunity to assess palliative care needs and deliver interventions.
OBJECTIVES: Synthesise the evidence regarding hospital palliative care (HPC) for patients with frailty. Narratively analyse the evidence regarding methods used to identify palliative care needs; types of palliative care interventions studied; and whether HPC improves outcomes.
METHODS: Systematic literature review and narrative synthesis of experimental, observational and systematic review articles investigating palliative care interventions for hospitalised adults aged ≥65 years with frailty. Electronic search of five databases from database inception to 30 January 2023. Included studies analysed using narrative synthesis according to Popay et al [4].
RESULTS: 15 465 titles retrieved, 12 included. Three studies detailed how they identified palliative care needs; all three used prognostication e.g. the 'surprise question'. Most papers (10/12) investigated specialist palliative care interventions. These interventions addressed a wider range of care needs than non-specialist interventions. Evidence suggested an improvement in some symptom burden and healthcare utilisation outcomes following HPC.
CONCLUSION: Prognostication was the main method of identifying palliative care needs, rather than individuals' specific needs. Specialist palliative care interventions were more holistic, indicating that non-specialist palliative care approaches may benefit from specialist team input. Despite suggestions of improvement in some outcomes with palliative care, heterogenous evidence prevented establishment of conclusive effects.
BACKGROUND: Paracetamol and ibuprofen are the most commonly used drugs for pain treatment in children and their combination has shown improved analgesic effect compared to treatment with either drug alone. Current literature lacks specific guidelines regarding the settings in which this combination should be adopted.
METHODS: The survey, conducted with Delphi methodology, involved 75 hospital and outpatient pediatricians with clinical experience in the management of pain in children. Pediatricians involved were asked to validate or not the results of the previous NominalGroup Tecnique (NGT) consensus and thus specify the optimal clinical settings in which the paracetamol/ibuprofen fixed-dose combination could be adopted.
RESULTS: The results confirm the importance of the fixed-dose paracetamol and ibuprofen combination for the control of mild-to-moderate acute pain in children. Particularly, this association seems to be appropriate in case of headache, earache, odontalgia and musculoskeletal pain, and in specific settings such as post-operative and post-procedural pain. The broadening of the panel brought to slight variations in clinical management practices between hospital and outpatient specialists. Nonetheless, overall consensus supports the notion that the fixed dose combination is more efficacious than monotherapies and it is well tolerated. Moreover, experts unanimously agree on the usefulness of the combination for caregivers, leading to improved adherence and effectiveness.
CONCLUSIONS: Both the NGT consensus and the broader Delphi consensus confirm the usefulness of the paracetamol-ibuprofen fixed-dose combination in pediatric pain. This is attributed to its superior effectiveness compared to monotherapies, a good tolerability profile, and improved compliance and ease of use. Some pain settings related to chronic, inflammatory and rheumatological pathologies remain to be investigated to evaluate the use of this combination.